Genetics of dementia

CONTINUUM Lifelong Learning in Neurology

Volumn 14, Issue 2, 2008, Pages 29-48

  St George Hyslop, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; DYNACTIN; NEUROSERPIN; PRESENILIN 1; PRESENILIN 2; PRION PROTEIN; PROGRANULIN; TAU PROTEIN; VALOSIN CONTAINING PROTEIN;

ALZHEIMER DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; DEMENTIA; DISEASE ASSOCIATION; DNA POLYMORPHISM; FRONTOTEMPORAL DEMENTIA; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HUMAN; NONHUMAN; PHARMACOGENETICS; REVIEW; RISK FACTOR;

EID: 42049095567     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000275624.01820.a9     Document Type: Review

References (56)

1. Aerssens J, Raeymaekers P, Lilienfeld S, et al. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12(2):69-77. Describes use of pharmacogenomics.
2. Aguzzi A, Heikenwalder M. Pathogenesis of prion diseases: current status and future outlook. Nat Rev Microbiol 2006;4(10):765-775. Reviews prion diseases.
3. Alberts MJ, Graffagnino C, McClenny C, et al. ApoE genotype and survival from intracerebral hemorrhage. Lancet 1995;346(8974):575. APOE is a risk factor for intracerebral hemorrhage. Suggests role for APOE in brain repair after many different types of brain injury.
4. Alzheimer Disease & Frontotemporal Dementia Mutation Database. http://www.molgen.ua.ac.be/ADMutations. Accessed January 7, 2008.
5. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442(7105):916-919. Describes mutations in progranulin as cause of tau-negative frontotemporal dementia (FTD).
6. Bird TD, Levy-Lahad E, Poorkaj P, et al. Wide range in age of onset for chromosome 1-related familial Alzheimer's disease. Ann Neurol 1996;40(6):932-936. Describes role of APOE in wide variations in age of onset in PS2 mutation carriers.
7. Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (Berl) 2007;114(1):5-22. New criteria for classifying FTD.
8. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nature Med 1997;3(1):67-72. Describes in vivo interaction of APP and PS1.
9. Copley TT, Wiggins S, Dufrasne S, et al. Are we all of one mind? Clinicians' and patients' opinions regarding the development of a service protocol for predictive testing for Huntington disease. Canadian Collaborative Study for Predictive Testing for Huntington Disease. Am J Med Genet 1995;58(1):59-69. A protocol for presymptomatic testing in early-onset autosomal dominant incurable neurodegenerative diseases.
10. Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006;442(7105):920-924. Describes mutations in progranulin as a cause of FTD.
11. Davis RL, Shrimpton AE, Holohan PD, et al. Familial dementia caused by polymerization of mutant neuroserpin. Nature 1999;401(6751):376-379. Describes mutations in neuroserpin as a cause of inherited dementia.
12. De Strooper B, Annert W, Cupers P, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999;398(6727):518-522. Describes the role of the presenilins in γ-secretase activity.
13. Farrer LA, Sherbatich T, Keryanov SA, et al. Association between angiotensin-converting enzyme and Alzheimer disease. Arch Neurol 2000;57(2):210-214. Describes ACE1 as a candidate gene for AD.
14. Freedman M. Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches. Can J Neurol Sci 2007;34(suppl 1):118-124. Reviews nosology of FTD and its applications.
15. Graff-Radford NR, Woodruff BK. Frontotemporal dementia. Semin Neurol 2007;27(1):48-57. Reviews FTD.
16. Gu Y, Chen F, Sanjo T, et al. APH-1 interacts with mature and immature forms of presenilins and nicastrin and may play a role in maturation of presenilin-nicastrin complexes. J Biol Chem 2003;278(8):7374-7380. Describes assembly of the presenilin γ-secretase complex.
17. Herms J, Anliker B, Heber S, et al. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J 2004;23(20):4106-4115. Describes the effect of knocking out more than one APP-like gene; suggests that this family has critical, but overlapping, activities.
18. Herreman A, Hartmann D, Annaert W, et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci USA 1999;96(21):11872-11877. Describes effect of knocking out PS2 - suggests that PS1 and PS2 actually have little redundancy.
19. Human Prion Point Mutations. http://www.mad-cow.org/ prion_point_mutations.html. Updated November 16, 2000. Accessed September 13, 2007.
20. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001;292(5521):1550-1552. Shows that neprilysin is a key enzyme involved in APP and Aβ metabolism.
21. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325(6106):733-736. Describes cloning of APP.
22. Kim SH, Wang R, Gordon DJ, et al. Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia. Nature Neurosci 1999;2(11):984-988. Describes mechanism by which familial British dementia and familial Danish dementia occur.
23. Kimonis VE, Watts GD. Autosomal dominant inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Alzheimer Dis Assoc Disord 2005;19(suppl 1):44-47. Describes mutations causing FTD and Paget disease.
24. Lautenschlager NT, Cupples LA, Rao VS, et al. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: what is in store for the oldest old? Neurology 1996;46(3):641-650. Epidemiologic analysis suggests multiple genes cause Alzheimer disease (AD).
25. Lee JH, Mayeux R, Mayo D, et al. Fine mapping of 10q and 18q for familial Alzheimer's disease in Caribbean Hispanics. Mol Psychiatry 2004;9(11):1042-1051. Describes a new AD locus on chromosome 18.
26. Levy JR, Sumner CJ, Caviston JP, et al. A motor neuron disease-associated mutation in p150Glued perturbs dynactin function and induces protein aggregation. J Cell Biol 2006;172(5):733-745. Protein aggregation mechanisms.
27. Masellis M, Momeni P, Meschino W, et al. Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain 2006;129(pt 11):3115-3123. Progranulin mutations cause corticobasal disease or FTD.
28. Mayeux R, Ottman R, Maestre G, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 1995;45(3 pt 1):555-557. APOE modulates risk of AD.
29. Mayeux R, Saunders AM, Shea S, et al; Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease [published erratum appears in N Engl J Med 1998;338(18):1325]. N Engl J Med 1998;338(8):506-511. Estimates diagnostic value of clinical APOE genotyping in AD.
30. McColl BW, McGregor AL, Wong A, et al. APOE epsilon3 gene transfer attenuates brain damage after experimental stroke. J Cereb Blood Flow Metab 2007;27(3):477-487. Suggests that a principal mechanism of APOE's effect is on brain repair following diverse injuries.
31. Momeni P, Schymick J, Jain S, et al. Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol 2006;6:44. Another gene causing FTD. Suggests FTD is a constellation of mechanistically unrelated diseases, such as Parkinson disease.
32. Myers A, Holmans P, Marshall H, et al. Susceptibility locus for Alzheimer's disease on chromosome 10. Science 2000;290(5500):2304-2305. Maps a new locus for AD to chromosome 10.
33. National Institute on Aging/Alzheimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet 1996;347(9008):1091- 1095. Recommendations for limited use of APOE genotyping as a presymptomatic test, at least until an effective treatment is found.
34. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314(5796):130-133. Identifies a protein that accumulates in some cases of ALS and/or FTD.
35. Newman MF, Croughwell ND, Blumenthal JA, et al. Predictors of cognitive decline after cardiac operation. Ann Thorac Surg 1995;59(5):1326- 1330. APOE is a risk factor for poor cognitive outcome after cardiac surgery.
36. Olichney JM, Hansen LA, Galasko D, et al. The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and in Lewy body variant. Neurology 1996;47(1):190-196. APOE is also a risk factor for dementia with Lewy bodies.
37. Olson JM, Goddard KA, Dudek DM. A second locus for very-late-onset Alzheimer disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. Am J Hum Genet 2002;71(1):154-161. Another putative AD locus.
38. Pardossi-Piquard R, Petit A, Kawarai T, et al. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron 2005;46(4):541-554. Describes the interaction of Aβ producing and degradation pathways via the presenilin γ-secretase.
39. Pericak-Vance MA, Bass MP, Yamaoka LH, et al. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA 1997;278(15):1237-1241. A putative AD locus on chromosome 12.
40. Pericak-Vance MA, Grubber J, Bailey LR, et al. Identification of novel genes in late-onset Alzheimer's disease. Exp Gerontol 2000;35(9-10):1343-1352. A putative AD locus on chromosome 12.
41. Qiu WQ, Walsh DM, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998;273(49):32730-32738. Insulin-degrading enzyme is another putative Aβ degrading enzyme.
42. Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:71-77. Reviews clinical evidence for and against the role of statins in preventing AD.
43. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995;376(6543):775-778. Describes cloning of PS2 as an AD gene.
44. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007;39(2):168-177. Identifies SORL1 as an AD gene.
45. Rogaeva EA, Fafel KC, Song YQ, et al. Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology 2001;57(4):621-625. Describes cost-effective protocol for screening for PS1 mutation in families with dementia.
46. Roses AD, Saunders AM, Huang Y, et al. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J 2007;7(1):10-28. Reviews role of pharmacogenomics in AD.
47. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43(8):1467-1472. Describes APOE ε4 as an AD risk allele.
48. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90(20):9649-9653. Describes greater deposition of brain amyloid in AD patients with APOE ε4.
49. Scott WK, Hauser ER, Schmechel DE, et al. Ordered-subsets linkage analysis detects novel Alzheimer disease loci on chromosomes 2q34 and 15q22. Am J Hum Genet 2003;73(5):1041-1051. Describes two putative AD loci.
50. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early onset familial Alzheimer's disease. Nature 1995;375(6534):754-760. Describes cloning of PS1.
51. Skibinski G, Parkinson NJ, Brown JM, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 2005;37(8):806-808. Describes mutations causing FTD.
52. St George-Hyslop P, McLachlan DC, Tsuda T, et al. Alzheimer's disease and possible gene interaction [published erratum appears in Science 1994;263(5149):904]. Science 1994;263(5146):537. Describes gene:gene interactions in AD.
53. Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotypes in the prediction of outcome in patients with memory impairment. Neurology 1996;46(1):149-154. Suggests that APOE genotyping adds little to patient-specific predictions about which patients with mild cognitive impairment will progress to AD.
54. Vassar R, Bennett BD, Babu-Kahn S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286(5440):735-741. Describes BACE/β-secretase as the first of two enzymes needed to cleave APP and generate Aβ.
55. Vidal R, Frangione B, Rostagno A, et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999;399(6738):776-781. Describes mutations causing familial British dementia.
56. Yu G, Nishimura M, Arawaka S, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature 2000;407(6800):48-54. Describes nicastrin, the substrate-binding protein of the presenilin/γ-secretase complex.